Country: Israel
Language: Hebrew
Source: Ministry of Health
AMIODARONE HYDROCHLORIDE
SANOFI ISRAEL LTD
C01BD01
תמיסה להזרקה
AMIODARONE HYDROCHLORIDE 50 MG / 1 ML
תוך-ורידי
מרשם נדרש
SANOFI WINTHROP INDUSTRIE, FRANCE
AMIODARONE
AMIODARONE
Corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.
2014-05-31
1 1. NAME OF THE MEDICINAL PRODUCT Amiodacore Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 3 ml ampoule contains 150 mg amiodarone hydrochloride. For excipients, see 6.1. 3. PHARMACEUTICAL FORM Solution for injection. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Treatment should be initiated and normally monitored only under hospital or specialist supervision. Amiodacore Injection is indicated for coronary insufficiency, arrhythmias resistant to other treatments, Wolff-Parkinson-White syndrome. Amiodacore Intravenous can be used where a rapid response is required or where oral administration is not possible. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Amiodacore Injection should only be used when facilities exist for cardiac monitoring, defibrillation, and cardiac pacing. Amiodacore Injection may be used prior to DC cardioversion. The standard recommended dose is 5 mg/kg bodyweight given by intravenous infusion over a period of 20 minutes to 2 hours. This should be administered as a dilute solution in 250 ml 5% dextrose. This may be followed by repeat infusion of up to 1200 mg (approximately 15 mg/kg bodyweight) in up to 500 ml 5% dextrose per 24 hours, the rate of infusion being adjusted on the basis of clinical response (see section 4.4). In extreme clinical emergency the drug may, at the discretion of the clinician, be given as a slow injection of 150 - 300 mg in 10 - 20 ml 5% dextrose over a minimum of 3 minutes. This should not be repeated for at least 15 minutes. Patients treated in this way with Amiodacore Injection must be closely monitored, e.g. in an intensive care unit (see section 4.4). After dilution in 5% dextrose solution, the diluted solution should be used immediately. 2 Changeover from Intravenous to Oral therapy As soon as an adequate response has been obtained, oral therapy should be initiated concomitantly at the usual loading dose (i.e. 200 mg three times a day). Amiodacore Injection should then be phased out gradually. Paediatric population The safety and efficacy of amio Read the complete document